Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aspen Faces Vaccine Setback In South Africa As Strides Explores Oral COVID Treatment

Dr Reddy’s, Lupin, Cipla And Sun Pharma Partner With Eli Lilly For Baricitinib In India

Executive Summary

After a production setback, Aspen and Johnson & Johnson announce a donation of 300,000 vaccines to South African teachers. Strides partners with Ennaid for an oral COVID drug, while Dr Reddy’s, Lupin, Cipla and Sun Pharma Partner with Eli Lilly for baricitinib in India and Formycon receives approval for early action for its COVID-19 drug.

You may also be interested in...



Alvogen Companies Donate To Support COVID Vaccines

Alvogen and sister company Alvotech have donated to UNICEF to support vaccine supply to over 90 low-and-middle-income countries, while Hikma has also made a multi-million-dollar donation. India’s Dr Reddy’s is moving ahead with the Sputnik V vaccine, while AstraZeneca is partnering with Insud Pharma on its vaccine in Spain. Meanwhile, the UK government has extended its vaccination contract with Wockhardt.

Pfizer Takes ‘Opportunistic’ Approach To Future Biosimilars

Pfizer reported double-digit growth in its biosimilars and sterile injectables segments, as the company indicated that it would take a more “opportunistic” approach to its biosimilars business in future. The company has also revised its overall 2021 financial guidance as it expects better numbers on the back of its COVID-19 vaccine business.

BioXpress And Abzena Partner On Biosimilar Development

BioXpress Therapeutics and Abzena, two service providers with expertise in biosimilar development, have partnered to support biosimilar development for third party customers. The companies plan to offer a “flexible and innovative approach from small scale biosimilar development through to large scale manufacturing.” 

Topics

Related Companies

UsernamePublicRestriction

Register

GB151024

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel
;